ABSTRACT
Background following a first cutaneous squamous cell carcinoma (CSCC), one-third of patients develop new primaries, escalating their risk of metastasis and poor outcomes. However, current follow-up strategies are not risk-stratified, representing a critical gap in patient management.
Objective to develop and validate a prognostic model to quantify individualized absolute risk of a first metachronous CSCC after an index tumor, accurately accounting for the high competing risk of mortality in this typically elderly population.
Methods we conducted a nationwide, population-based cohort study of 11,737 patients with a first histologically confirmed CSCC (Netherlands Cancer Registry, 2007–2008) with up to 10 years of follow-up. Data on subsequent tumors was retrieved via linkage to the Automated National Pathological Anatomy Archive (Palga). A Fine–Gray competing-risk model was developed using routinely available clinical and pathological predictors (age, sex, hematologic malignancy, basal cell carcinoma (BCC) and actinic keratosis (AK) history, presence of synchronous CSCC, primary tumor location, and differentiation). Model performance was assessed 10-fold cross-validation, quantifying discrimination (time-dependent C-index) and calibration.
Results during follow-up, 3,288 (28%) developed a first metachronous CSCC. The model identified key predictors: markers of cumulative UV-exposure (included AK history, ≥5 prior BCCs), and immunosuppression (chronic lymphocytic leukaemia/small lymphocytic leukaemia). Male sex, presence of synchronous CSCC at baseline were also associated with higher risk. While discrimination was modest (cross-validated 5-year C-index: 0.64), the model demonstrated excellent calibration.
Conclusions this competing-risk model provides individualized, well-calibrated absolute risk estimates for a first metachronous CSCC. Based on routinely available clinical features, it offers insight into how established predictors shape risk in this high-susceptibility population. External validation and the identification of novel predictors are necessary to further refine the model and support personalized dermatologic care.
Competing Interest Statement
M.W. has received honoraria for lectures and advisory board meetings from Sanofi, Regeneron and Sun Pharma. T.N. is head of the dermatology department of the Erasmus MC and a section editor for the BJD. BRP is funded by a PPP Allowance made available by Health ∼ Holland, Top Sector Life Sciences & Health, to stimulate public–private partnerships, of which SkylineDx is a contributing member. The remaining authors state no conflicts of interest.
Funding Statement
This study was supported by an independent research grant provided by the Erasmus Foundation and Alphatron.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval status: This study was approved by the scientific committees of the NCR, Palga, Erasmus Medical Center (MEC-2020-0054), and Dutch Clinical Research Foundation (W20.048/NWMO20.02.007). thics statement and patient consent: According to the Central Committee on Research involving Human Subjects (CCMO), this observational, non–interventional study does not require approval from an ethics committee. A waiver of informed consent was granted following the code of conduct of the Foundation Federation of Dutch Medical Scientific Societies.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* ML and LH share joint senior authorship.
Data availability
The data presented in this study are provided by the Netherlands Cancer Registry to the Erasmus MC Institute and are therefore not publicly available. However, these data may be available upon reasonable request to the corresponding author and with permission of the Netherlands Cancer Registry.
ABBREVIATIONS
- CSCC
- Cutaneous squamous cell carcinoma
- Palga
- Automated National Pathological Anatomy Archive
- NCR
- Netherlands Cancer Registry
- ICD-O-3
- International Classification of Diseases for Oncology, third edition
- SOTR
- Solid organ transplant recipients
- NOTR
- Netherlands Organ Transplant Registry
- BCC
- Basal cell carcinoma
- AK
- Actinic keratosis
- HM
- Hematologic malignancy
- CLL/SLL
- Chronic lymphocytic leukemia / Small lymphocytic leukemia
- FGM
- Fine and Gray model
- CCA
- Complete case analysis
- SHR
- Subdistribution hazard ratio
- NPV
- Negative predicted value
- UV
- Ultraviolet
